# Competitive Pipeline Report — Johnson & Johnson

## Executive summary
- Run date (UTC): 2026-01-07
- Source: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
- Extracted 'as of' date: October 14, 2025
- Programs extracted: 101

### Pipeline size by phase (snapshot)
- Unknown: 101

## Change log (previous vs current)
### NEW_ASSET
- What changed: JNJ-1887 sCD59: new asset added to pipeline
- Confidence (pre-corroboration): 0.65
- Why it matters: J&J has clarified the nomenclature for its Geographic Atrophy candidate, JNJ-1887, indicating it targets sCD59. This highlights a specific mechanism of action in a competitive ophthalmology space.
- Watch items:
  - Phase progression and clinical trial designs for JNJ-1887 sCD59.
  - Public disclosure of mechanism of action data.
  - Competitor pipelines targeting complement pathways in Geographic Atrophy.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_ASSET
- What changed: JNJ-1900 (NBTXR3): new asset added to pipeline
- Confidence (pre-corroboration): 0.65
- Why it matters: J&J has specified its oncology asset JNJ-1900 as NBTXR3, a radioenhancer from partner Nanobiotix, for Head and Neck and Lung Cancers. This clarifies J&J's involvement in a novel radiation therapy enhancement approach.
- Watch items:
  - Clinical trial progress and data for NBTXR3 in these indications.
  - Regulatory filings and potential approvals for NBTXR3.
  - Development of competing radioenhancers.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_ASSET
- What changed: JNJ-2056 (tau active immunotherapy): new asset added to pipeline
- Confidence (pre-corroboration): 0.65
- Why it matters: J&J has updated its Alzheimer's pipeline to explicitly identify JNJ-2056 as a tau active immunotherapy, ACI-35.030, in partnership with AC Immune SA. This reaffirms J&J's commitment to addressing tau pathology, a critical target in Alzheimer's.
- Watch items:
  - Clinical data readouts from the RETAIN trial.
  - Progression of other tau-targeting therapies in Alzheimer's.
  - J&J's broader Alzheimer's disease strategy.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_ASSET
- What changed: milvexian (Factor Xla): new asset added to pipeline
- Confidence (pre-corroboration): 0.65
- Why it matters: J&J has clarified its partnered asset, milvexian, explicitly as a Factor XIa inhibitor, for cardiovascular indications like stroke prevention, ACS, and AF. This emphasizes a key pipeline asset with significant potential in antithrombotic therapy, a large market.
- Watch items:
  - Phase 3 trial results (e.g., OCEANIC program) for milvexian.
  - Regulatory submissions and approval timelines.
  - Competitive landscape for novel oral anticoagulants and Factor XIa inhibitors.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_ASSET
- What changed: JNJ-1887: removed from pipeline (possible discontinuation or deprioritization)
- Confidence (pre-corroboration): 0.60
- Why it matters: The removal of JNJ-1887 concurrent with the addition of 'JNJ-1887 sCD59' indicates a nomenclature clarification rather than a true asset discontinuation. This updates the asset's tracking to explicitly include its mechanism of action.
- Watch items:
  - Confirmation that JNJ-1887 sCD59 is the direct continuation of JNJ-1887.
  - Any public statements from J&J regarding this pipeline update.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_ASSET
- What changed: JNJ-1900: removed from pipeline (possible discontinuation or deprioritization)
- Confidence (pre-corroboration): 0.60
- Why it matters: The removal of JNJ-1900 simultaneous with the addition of 'JNJ-1900 (NBTXR3)' signifies a nomenclature clarification for this oncology asset. This aligns the pipeline tracking with its specific identity as Nanobiotix's NBTXR3.
- Watch items:
  - Confirmation that JNJ-1900 (NBTXR3) is the direct continuation of JNJ-1900.
  - Updates on the development status of NBTXR3 by Nanobiotix.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_ASSET
- What changed: JNJ-2056: removed from pipeline (possible discontinuation or deprioritization)
- Confidence (pre-corroboration): 0.60
- Why it matters: The removal of JNJ-2056, immediately followed by the addition of 'JNJ-2056 (tau active immunotherapy)', indicates a formal clarification of the asset's name and mechanism. This ensures more precise tracking of J&J's Alzheimer's disease pipeline.
- Watch items:
  - Confirmation that JNJ-2056 (tau active immunotherapy) is the direct continuation of JNJ-2056.
  - Public communications detailing the significance of this naming update.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_ASSET
- What changed: milvexian: removed from pipeline (possible discontinuation or deprioritization)
- Confidence (pre-corroboration): 0.60
- Why it matters: The removal of 'milvexian' alongside the addition of 'milvexian (Factor XIa)' suggests a clarification of the asset's mechanism of action in the pipeline tracking. This provides more specific details about J&J's partnered antithrombotic program.
- Watch items:
  - Confirmation that milvexian (Factor XIa) is the direct continuation of milvexian.
  - Any joint statements from J&J and BMS on this asset's development.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_INDICATION
- What changed: AKEEGA (niraparib/abiraterone): new indication added — M1 Metastatic Castration-Sensitive Prostate Cancer
- Confidence (pre-corroboration): 0.60
- Why it matters: J&J has clarified the specific indication for AKEEGA (niraparib/abiraterone) as M1 Metastatic Castration-Sensitive Prostate Cancer, reflecting ongoing development in an area with high unmet need. This formalizes a key lifecycle management strategy for their oncology franchise.
- Watch items:
  - Regulatory updates for AKEEGA in this indication.
  - Commercial launch and uptake post-approval.
  - Competitor activity in mCSPC.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: AKEEGA (niraparib/abiraterone): indication removed — None
- Confidence (pre-corroboration): 0.55
- Why it matters: The removal of a generic/null indication for AKEEGA is a standard pipeline hygiene update, replaced by the specific M1 Metastatic Castration-Sensitive Prostate Cancer indication. This indicates more precise tracking of this key oncology combination.
- Watch items:
  - Confirmation that the specific new indication adequately covers the previous 'null' entry.
  - Any impact on broader perception of AKEEGA's development strategy.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: DARZALEX (daratumumab): indication removed — M1 Metastatic Castration-Sensitive Prostate Cancer
- Confidence (pre-corroboration): 0.55
- Why it matters: J&J has removed the M1 Metastatic Castration-Sensitive Prostate Cancer indication for DARZALEX from its pipeline. This suggests a strategic deprioritization or discontinuation of this particular development path, potentially due to trial results or shifting oncology priorities.
- Watch items:
  - Official communication from J&J regarding this decision.
  - Impact on Darzalex's long-term lifecycle strategy in prostate cancer.
  - Reallocation of resources to other Darzalex indications or prostate cancer assets.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: icotrokinra: indication removed — Pediatric Crohn's Disease
- Confidence (pre-corroboration): 0.55
- Why it matters: The removal of 'icotrokinra' for Pediatric Crohn's Disease, alongside other icotrokinra indications, strongly suggests this was a placeholder asset now formally attributed to TREMFYA (guselkumab) or deprioritized.
- Watch items:
  - Confirmation from J&J regarding the status of 'icotrokinra'.
  - Updates on Tremfya's pediatric IBD development, especially for Crohn's Disease.
  - Any public data that led to the removal of this program.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: icotrokinra: indication removed — Pediatric Juvenile Psoriatic Arthritis
- Confidence (pre-corroboration): 0.55
- Why it matters: The removal of 'icotrokinra' for Pediatric Juvenile Psoriatic Arthritis, aligning with the addition of this indication for TREMFYA, indicates a pipeline tracking clarification. 'Icotrokinra' was likely a placeholder now formally assigned to guselkumab.
- Watch items:
  - Official confirmation that Tremfya (guselkumab) is now the designated asset for this indication.
  - Any remaining ambiguity around the 'icotrokinra' program.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: icotrokinra: indication removed — Pediatric Ulcerative Colitis
- Confidence (pre-corroboration): 0.55
- Why it matters: The removal of 'icotrokinra' for Pediatric Ulcerative Colitis, coinciding with the addition of this indication for TREMFYA, suggests a pipeline update to assign development to the correct asset. This reflects improved data hygiene.
- Watch items:
  - Official confirmation that Tremfya (guselkumab) is now the designated asset for this indication (QUASAR JR).
  - Updates on the QUASAR JR trial progress.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: icotrokinra: indication removed — Psoriatic Arthritis Structural Damage
- Confidence (pre-corroboration): 0.55
- Why it matters: The removal of 'icotrokinra' for Psoriatic Arthritis Structural Damage, aligning with the addition of this indication for TREMFYA, indicates a pipeline tracking clarification. 'Icotrokinra' was likely a placeholder now formally assigned to guselkumab.
- Watch items:
  - Official confirmation that Tremfya (guselkumab) is now the designated asset for this indication (APEX).
  - Updates on the APEX trial progress.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: icotrokinra: indication removed — Ulcerative Colitis Subcutaneous Induction
- Confidence (pre-corroboration): 0.55
- Why it matters: The removal of 'icotrokinra' for Ulcerative Colitis Subcutaneous Induction, coinciding with the addition of this indication for TREMFYA, suggests a pipeline update to assign development to the correct asset. This reflects improved data hygiene.
- Watch items:
  - Official confirmation that Tremfya (guselkumab) is now the designated asset for this indication (ASTRO).
  - Updates on the ASTRO trial progress.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_INDICATION
- What changed: RYBREVANT (amivantamab): new indication added — None
- Confidence (pre-corroboration): 0.60
- Why it matters: J&J is updating its pipeline to specifically track the subcutaneous formulation development for RYBREVANT (amivantamab), as indicated by the PALOMA-3 trial. This is a critical lifecycle management effort to improve patient convenience and potentially expand market reach in NSCLC.
- Watch items:
  - Results from the PALOMA-3 study comparing SC vs. IV formulations.
  - Regulatory filings and potential approval for the SC formulation.
  - Commercial strategy for the new formulation and impact on competitive landscape.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: RYBREVANT (amivantamab): indication removed — Non Small Cell Lung Cancer
- Confidence (pre-corroboration): 0.55
- Why it matters: The removal of a broad 'Non Small Cell Lung Cancer' indication for RYBREVANT with a 'Subcutaneous formulation development' note, replaced by a more specific 'Subcutaneous' entry, indicates a pipeline refinement. This highlights focused development on the SC formulation.
- Watch items:
  - Confirmation that the new entry accurately reflects the ongoing development for the SC formulation.
  - Any public communication clarifying the scope of the PALOMA-3 trial.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_INDICATION
- What changed: SIMPONI (golimumab): new indication added — Pediatric Ulcerative Colitis
- Confidence (pre-corroboration): 0.60
- Why it matters: J&J has added Pediatric Ulcerative Colitis as a specific indication for SIMPONI (golimumab), underscoring a strategic effort to expand the asset's label into underserved pediatric populations. This extends the commercial lifespan and value of an established biologic.
- Watch items:
  - Regulatory updates and potential approval timelines for this indication.
  - Market uptake and competitive dynamics in pediatric UC.
  - Further lifecycle management efforts for SIMPONI.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: SIMPONI (golimumab): indication removed — None
- Confidence (pre-corroboration): 0.55
- Why it matters: The removal of a generic/null indication for SIMPONI is a standard pipeline hygiene update, replaced by the specific Pediatric Ulcerative Colitis indication. This indicates more precise tracking of this mature asset.
- Watch items:
  - Confirmation that the specific new indication adequately covers the previous 'null' entry.
  - Any impact on broader perception of SIMPONI's development strategy.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_INDICATION
- What changed: STELARA (ustekinumab): new indication added — Pediatric Crohn's Disease
- Confidence (pre-corroboration): 0.60
- Why it matters: J&J has added Pediatric Crohn's Disease as a new indication for STELARA (ustekinumab), demonstrating continued investment in this key asset's lifecycle management. This aims to secure Stelara's position in a pediatric inflammatory bowel disease market.
- Watch items:
  - Regulatory filings and potential approval in pediatric Crohn's Disease.
  - Impact on Stelara's market share ahead of biosimilar entry.
  - Competition from other biologics in pediatric IBD.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: STELARA (ustekinumab): indication removed — None
- Confidence (pre-corroboration): 0.55
- Why it matters: The removal of a generic/null indication for STELARA is a standard pipeline hygiene update, replaced by the specific Pediatric Crohn's Disease indication. This indicates more precise tracking of this key IBD asset.
- Watch items:
  - Confirmation that the specific new indication adequately covers the previous 'null' entry.
  - Any impact on broader perception of STELARA's development strategy.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_INDICATION
- What changed: TALVEY + TECVAYLI: new indication added — TIE NDMM in combination with DR
- Confidence (pre-corroboration): 0.60
- Why it matters: J&J is advancing a combination therapy of TALVEY and TECVAYLI for TIE NDMM in combination with DR (Transplant Eligible Newly Diagnosed Multiple Myeloma with Daratumumab and Revlimid/other partner drug). This signifies J&J's aggressive strategy to combine its bispecific antibodies for deeper, earlier responses in multiple myeloma, a highly competitive area.
- Watch items:
  - Progress and interim data from the MajesTEC-7 trial.
  - Efficacy and safety profile of the combination vs. standard of care.
  - Competitive responses to this combination strategy in NDMM.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_INDICATION
- What changed: TREMFYA (guselkumab): new indication added — Pediatric Juvenile Psoriatic Arthritis
- Confidence (pre-corroboration): 0.60
- Why it matters: J&J has formally added Pediatric Juvenile Psoriatic Arthritis as a new indication for TREMFYA (guselkumab). This expands the asset's addressable market and strengthens its position in pediatric rheumatology, likely consolidating previously tracked placeholder programs.
- Watch items:
  - Regulatory filings and approvals for this indication.
  - Trial progress and data for guselkumab in pJIA/pPsA.
  - Market dynamics in pediatric autoimmune diseases.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_INDICATION
- What changed: TREMFYA (guselkumab): new indication added — Pediatric Psoriasis
- Confidence (pre-corroboration): 0.60
- Why it matters: J&J has formally added Pediatric Psoriasis as a new indication for TREMFYA (guselkumab), evidenced by the PROTOSTAR trial. This expands the asset's lifecycle management and strengthens its presence in the dermatology market for younger populations.
- Watch items:
  - Clinical data readouts from the PROTOSTAR trial.
  - Regulatory submissions and potential approvals.
  - Competitive landscape for pediatric psoriasis treatments.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_INDICATION
- What changed: TREMFYA (guselkumab): new indication added — Pediatric Ulcerative Colitis
- Confidence (pre-corroboration): 0.60
- Why it matters: J&J has formally added Pediatric Ulcerative Colitis as a new indication for TREMFYA (guselkumab), as part of the QUASAR JR trial. This signifies a strategic expansion into pediatric IBD, leveraging Tremfya's mechanism of action for a broader patient population.
- Watch items:
  - Trial results from QUASAR JR.
  - Regulatory filings and potential approvals for pediatric UC.
  - Competitive positioning against other biologics in pediatric IBD.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_INDICATION
- What changed: TREMFYA (guselkumab): new indication added — Psoriatic Arthritis Structural Damage
- Confidence (pre-corroboration): 0.60
- Why it matters: J&J has formally added Psoriatic Arthritis Structural Damage as a new indication for TREMFYA (guselkumab), supported by the APEX trial. This highlights an effort to demonstrate comprehensive disease modification, a key differentiator in the PsA market.
- Watch items:
  - Clinical data readouts from the APEX trial.
  - Regulatory implications of structural damage claims.
  - Competitive differentiation against other PsA therapies.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### NEW_INDICATION
- What changed: TREMFYA (guselkumab): new indication added — Ulcerative Colitis Subcutaneous Induction
- Confidence (pre-corroboration): 0.60
- Why it matters: J&J has formally added Ulcerative Colitis Subcutaneous Induction as a new indication for TREMFYA (guselkumab), supported by the ASTRO trial. This offers a convenient administration option for a critical phase of treatment, potentially enhancing market adoption.
- Watch items:
  - Trial results from the ASTRO study.
  - Regulatory filings and potential approvals for SC induction.
  - Physician and patient uptake of subcutaneous options in UC.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: TREMFYA (guselkumab): indication removed — None
- Confidence (pre-corroboration): 0.55
- Why it matters: The removal of a generic/null indication for TREMFYA is a standard pipeline hygiene update, replaced by several specific pediatric and adult indications. This reflects a maturation of J&J's tracking of its key IL-23 inhibitor.
- Watch items:
  - Confirmation that the specific new indications adequately cover the previous 'null' entry.
  - Any impact on broader perception of Tremfya's development strategy.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

### REMOVED_INDICATION
- What changed: TREMFYA (guselkumab): indication removed — Pediatric Crohn's Disease
- Confidence (pre-corroboration): 0.55
- Why it matters: J&J has removed Pediatric Crohn's Disease as a specific indication for TREMFYA (guselkumab). This suggests a strategic deprioritization or discontinuation of this particular development path, potentially due to trial results or shifting focus within its IBD portfolio.
- Watch items:
  - Official communication from J&J regarding this decision for pediatric Crohn's.
  - Impact on Tremfya's overall pediatric IBD strategy, especially with the addition of pediatric UC.
  - Competitor activity in pediatric Crohn's disease.
- Citations: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf

## Appendix: pipeline preview (first 15 rows)
- AKEEGA (niraparib/abiraterone) — M1 Metastatic Castration-Sensitive Prostate Cancer — Partner: TESARO, an oncology-focused business within GSK
- DARZALEX (daratumumab) — Smoldering Multiple Myeloma — Partner: Genmab A/S
- DARZALEX (daratumumab) — Frontline multiple myeloma transplant ineligible — Partner: Genmab A/S
- IMBRUVICA (ibrutinib) — Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) — Partner: Pharmacyclics, LLC, an AbbVie company
- IMBRUVICA (ibrutinib) — Frontline Mantle Cell Lymphoma — Partner: Pharmacyclics, LLC, an AbbVie company
- INLEXZO (gemcitabine intravesical system) — Non Muscle Invasive Bladder Cancer
- RYBREVANT (amivantamab) — Frontline Non Small Cell Lung Cancer in combination with chemotherapy
- RYBREVANT (amivantamab)
- Bleximenib — Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine
- CARVYKTI (Ciltacabtagene autoleucel) — Frontline Multiple Myeloma TNI — Partner: Legend Biotech
- CARVYKTI (Ciltacabtagene autoleucel) — Frontline Multiple Myeloma Transplant Eligible vs ASCT — Partner: Legend Biotech
- ERLEADA (apalutamide) — Localized Prostate Cancer — Partner: Regents of California and Memorial Sload Kettering
- ERLEADA (apalutamide) — High Risk Prostate Cancer — Partner: Regents of California and Memorial Sload Kettering
- INLEXZO (gemcitabine intravesical system) — Non Muscle Invasive Bladder Cancer BCG-naïve High Risk
- INLEXZO (gemcitabine intravesical system) — High Risk Non Muscle Invasive Bladder Cancer BGC Experienced

## Citations and provenance
- Source URL: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
- Previous snapshot file: snapshots/jnj/latest.json
